宁波美诺华药业股份有限公司 关于子公司盐酸鲁拉西酮原料药通过 CDE 技术审评的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，宁波美诺华药业股份有限公司（以下简称"公司"）子公司安徽美诺 华药物化学有限公司（以下简称"安徽美诺华"）收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请 批准通知书》，现就相关情况公告如下： | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-089 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 一、登记信息的主要内容 1 品种名称：盐酸鲁拉西酮 企业名称：安徽美诺华药物化学有限公司 企业地址：中国安徽广德经济技术开发区 受体（Ki=11nM）具有中度亲和力，是 5-羟色胺 5-HT1A（Ki=6.4nM）受体的部 分激动剂，也是α2A 肾上腺素受体（Ki=41nM）的拮抗剂。鲁拉西酮对组胺 H1 日和毒蕈碱 M1受体表现出较小的亲和力，或者无亲和力（IC50 ...

美诺华（603538）(603538.SH)公告，公司子公司安徽美诺华药物化学有限公司(简称"安徽美诺华")收到 国家药品监督管理局核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请批准通知书》，该药品适应 症为：用于治疗精神分裂症。 ...

智通财经APP讯，美诺华(603538.SH)公告，公司子公司安徽美诺华药物化学有限公司(简称"安徽美诺 华")收到国家药品监督管理局核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请批准通知书》，该 药品适应症为：用于治疗精神分裂症。 ...

人民财讯8月4日电，美诺华（603538）8月4日晚间公告，公司子公司安徽美诺华药物化学有限公司近日 收到国家药监局核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请批准通知书》。药品适应症：用 于治疗精神分裂症。 ...

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

资金流向方面，今日主力资金净流出1341.37万元，占比成交额1.74%。其中，超大单净流出3038.77万 元、占成交额3.95%，大单净流入1697.40万元、占成交额2.21%，中单净流出流出1314.66万元、占成交 额1.71%，小单净流入2656.03万元、占成交额3.45%。 美诺华最新一期业绩显示，截至2025一季报，公司营业总收入2.76亿元、同比增长5.22%，归属净利润 2122.17万元，同比增长51.12%，扣非净利润1662.24万元，同比减少19.02%，流动比率1.206、速动比率 0.651、资产负债率50.05%。 天眼查商业履历信息显示，宁波美诺华药业股份有限公司，成立于2004年，位于宁波市，是一家以从事 医药制造业为主的企业。企业注册资本21982.2861万人民币，实缴资本9000万人民币。公司法定代表人 为姚成志。 通过天眼查大数据分析，宁波美诺华药业股份有限公司共对外投资了16家企业，参与招投标项目6次， 知识产权方面有商标信息1条，专利信息27条，此外企业还拥有行政许可9个。 来源：金融界 金融界消息 截至2025年7月30日收盘，美诺华（603538）报收于 ...

Investment Rating - The report maintains a positive outlook on innovative drugs and the industry chain, recommending continuous attention to this sector [1][5][24]. Core Viewpoints - The report highlights the sustained high prosperity of innovative drugs, with a focus on companies likely to see a revaluation, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Huadong Medicine. It also emphasizes Biopharma/Biotech companies with innovative pipelines entering a growth phase, including PATEO, Innovent Biologics, BeiGene, and others [1][5][24]. - The A-share pharmaceutical sector outperformed the market in the third week of July 2025, with a 4.0% increase compared to a 0.7% rise in the Shanghai Composite Index. The report notes that the premium of the pharmaceutical sector relative to all A-shares is currently at a normal level of 86.8% [7][25][16]. - The Hong Kong pharmaceutical sector showed outstanding performance, with the Hang Seng Healthcare index rising by 12.0% and the Hong Kong Biotechnology index increasing by 13.6% during the same period [21][25]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Industry Chain - The report emphasizes the ongoing high demand for innovative drugs and recommends companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others for potential investment [1][5][24]. 2. Performance of A-Shares Pharmaceutical Sector - In the third week of July 2025, the A-share pharmaceutical sector led with a 4.0% increase, outperforming the overall market. Notable sub-sectors included chemical raw materials and chemical preparations, with gains of 7.0% and 6.8% respectively [7][11][25]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector performed exceptionally well, with significant gains in the Hang Seng Healthcare and Biotechnology indices. In contrast, the U.S. pharmaceutical sector underperformed, with a decline of 2.5% in the S&P 500 Healthcare Select Sector [21][25].

Group 1 - The core viewpoint of the article highlights the significant growth in China's innovative drug development pipeline, which accounts for approximately 25% of the global total [1] - The Director of the Drug Registration Management Department of the National Medical Products Administration, Yang Ting, stated that around 3,000 clinical trial projects are conducted annually in China, placing the country among the leaders globally in this area [1] Group 2 - The stock prices of several companies in the pharmaceutical sector, including Boteng Co., Ltd., Kanglong Chemical, and Haitai Biological, saw notable increases, with Boteng Co., Ltd. rising nearly 10% and others rising over 5% [1] - The positive sentiment in the market is likely driven by the announcement regarding China's strong position in innovative drug development and clinical trials [1]